CN102872140B - Application of Houttuynoid C in drug for treating acute renal failure - Google Patents
Application of Houttuynoid C in drug for treating acute renal failure Download PDFInfo
- Publication number
- CN102872140B CN102872140B CN 201210419602 CN201210419602A CN102872140B CN 102872140 B CN102872140 B CN 102872140B CN 201210419602 CN201210419602 CN 201210419602 CN 201210419602 A CN201210419602 A CN 201210419602A CN 102872140 B CN102872140 B CN 102872140B
- Authority
- CN
- China
- Prior art keywords
- houttuynoid
- renal failure
- acute renal
- drug
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The invention relates to the new medical use of Houttuynoid C, namely application of Houttuynoid C in preparing a drug for treating acute renal failure. The use of Houttuynoid C in preparing the drug for treating the acute renal failure involved in the invention is disclosed for the first time; as the framework type of Houttuynoid C is a brand new framework type and Houttuynoid C has an unexpectedly high inhibition activity for the acute renal failure without possibility of giving any implication by other compounds, Houttuynoid C has outstanding substantive features; and simultaneously, the application of Houttuynoid C for preventing acute renal failure apparently has obvious progress.
Description
Technical field
The present invention relates to the pharmaceutical chemistry field.Particularly, the present invention relates to the novel medical use of Houttuynoid C, i.e. the application of Houttuynoid C in preparation treatment acute renal failure medicine.
Background technology
Acute renal failure (Acute Renal Failure, ARF) be the clinical syndrome that is caused by multiple reason, be found in clinical each patient of section, sickness rate is high and often have serious consequences, (a few hours are to a couple of days) siddhi can sharply descend its characteristics in a short time, clinical manifestation is acute oliguria (urine amount＜400mLPd) or anuria (urine amount＜100mLPd), nitrogen matter metabolite is discharged and is produced obstacle in the body, azotemia appears rapidly, water and electrolyte, acid base imbalance, and cause each system's corresponding function imbalance of whole body.The principal element that causes acute renal failure is the rapid minimizing of renal blood flow, and because oxidative stress and the cell injury that the nephridial tissue ischemia causes finally causes the deterioration of renal tissue structural damage and function.Still there is not at present the effective medicine for the treatment of acute renal failure of generally acknowledging clinically, only can be by correcting water-electrolyte balance, symptomatic treatment measures such as correction acidosis improve symptom, and the later stage also needs to keep the body function by hemodialysis.There is the clinical medicine of obvious curative effects rare aspect the nephridial tissue damage improving renal blood flow perfusion obstacle and alleviate.
The compound H outtuynoid C that the present invention relates to is one and delivered (Chen in 2012, S. D. et al., 2012. Houttuynoid C_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.) new framework compound, this chemical compound has brand-new framework types, present purposes only relates to anti-herpes simplex virus activity (Chen, S. D. et al., 2012. Houttuynoid C_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.), belong to open first for the purposes of the Houttuynoid C that the present invention relates in the anti-acute renal failure medicine of preparation, because framework types belongs to brand-new framework types, and it suppresses active unexpectedly strong for acute renal failure, there is not the possibility that is provided any enlightenment by other chemical compounds, possess outstanding substantive distinguishing features, be used for anti-acute renal failure simultaneously and obviously have obvious improvement.
Summary of the invention
The purpose of this invention is to provide the purposes that Houttuynoid C is used for the treatment of acute renal failure, namely for the preparation of the purposes for the treatment of the acute renal failure medicine.
Houttuynoid C of the present invention is, and the acute renal failure disease has the obvious treatment effect.
By our discovering, the anuria when Houttuynoid C can improve acute renal failure or oliguria symptom, the function of protection kidney.
Described compound H outtuynoid C-structure is shown in formula I:
Formula I
The purposes of the Houttuynoid C that the present invention relates in the anti-acute renal failure medicine of preparation belongs to open first, because framework types belongs to brand-new framework types, and it suppresses active unexpectedly strong for acute renal failure, there is not the possibility that is provided any enlightenment by other chemical compounds, possess outstanding substantive distinguishing features, be used for anti-acute renal failure simultaneously and obviously have obvious improvement.
The specific embodiment
The preparation method of compound H outtuynoid C involved in the present invention is referring to document (Chen, S. D. et al., 2012. Houttuynoid C_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
Embodiment 1: the preparation of compound H outtuynoid C tablet involved in the present invention:
Get 20 and digest compound Houttuynoid C, add conventional adjuvant 180 grams of preparation tablet, mixing, conventional tablet machine are made 1000.
Embodiment 2: the preparation of compound H outtuynoid C capsule involved in the present invention:
Get 20 and digest compound Houttuynoid C, add conventional adjuvant such as starch 180 grams of preparation capsule, mixing is encapsulatedly made 1000.
Further specify its pharmaceutically active below by pharmacodynamic experiment.
Further specify its pharmaceutically active below by pharmacodynamic experiment.
The therapeutical effect of the acute renal failure rat of experimental example 1 Houttuynoid C
(1) experimental technique
Adopt intramuscular injection glycerol to cause the acute renal failure rat animal model.Select 60 of the healthy male SD rats of 180 ~ 220g for use, be divided into 5 groups at random: sham operated rats (intramuscular injection normal saline); Model group (intramuscular injection glycerol); Houttuynoid C I group (0.3 mg/Kg)); Houttuynoid C II group (0.6 mg/Kg)); Houttuynoid C III group (1.2 mg/Kg)), each organizes rat tail vein injection saline or Houttuynoid C immediately after the glycerol modeling, is administered once after 12 and 24 hours again.
(2) observation index
60 rat lasts give to put into metabolic cage collection twenty-four-hour urine behind Houttuynoid C or the normal saline, stay back 6 hours of urine with 4% chloral hydrate intraperitoneal injection of anesthesia, adopt laser Doppler flowmetry to measure after the modeling and treatment back bilateral renal blood flow amount, average as single animal renal blood flow; Get blood and prepare serum, measure blood BUN and Cre; Get kidney, prepare 10% renal cortex homogenate, measure renal cortex homogenate MDA, GSH, NO(all by the operation of test kit description).
(3) experimental result
1. Houttuynoid C can increase acute renal failure mice renal blood flow
The influence of the acute renal failure mice of table 1 Houttuynoid C renal blood flow
* P＜0.05vs acute renal failure model group
2. the acute renal failure mice of Houttuynoid C renal function tool protective effect
The model group rat significantly reduces than sham operated rats rat twenty-four-hour urine amount, is respectively 4.57 ± 0.74ml and 11.82 ± 2.36ml; Middle and high dosage Houttuynoid C group twenty-four-hour urine amount is significantly higher than model group (P＜0.05), and the urine measurer of three medication therapy groups has dose dependent, is respectively I group 5.41 ± 0.83ml, II group 7.84 ± 1.12ml, III group 9.61 ± 1.20ml.Illustrate that Houttuynoid C can improve the oliguria symptom of acute renal failure rat.
Acute renal failure rat intravenous injection normal saline is after 24 hours, and serum BUN is 25.53 ± 1.62mmol/L, and Cre is 168.56 ± 13.01umol/L, apparently higher than sham operated rats, illustrates that model group animal renal function injury is serious.Middle and high dosage Houttuynoid C can improve the renal function (P＜0.05) of acute renal failure rat in dose dependent ground.See Table 2.
Each rats in test groups renal function index of table 2 relatively
* P＜0.05vs acute renal failure model group
Conclusion: the anuria when Houttuynoid C can improve acute renal failure or oliguria symptom, the function of protection kidney can be used for preparing anti-acute renal failure medicine.
Claims (1)
1.Houttuynoid the application of C in preparation treatment acute renal failure medicine, described compound H outtuynoid C-structure as
Formula IShown in:
Formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210419602 CN102872140B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid C in drug for treating acute renal failure |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210419602 CN102872140B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid C in drug for treating acute renal failure |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102872140A CN102872140A (en) | 2013-01-16 |
| CN102872140B true CN102872140B (en) | 2013-08-28 |
Family
ID=47473811
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201210419602 Expired - Fee Related CN102872140B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid C in drug for treating acute renal failure |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102872140B (en) |
-
2012
- 2012-10-27 CN CN 201210419602 patent/CN102872140B/en not_active Expired - Fee Related
Non-Patent Citations (2)
| Title |
|---|
| ChenSDetal.HouttuynoidsA-E anti-herpes simplex virus active flavonoids with novel skeletons from Houttuynia cordata.《organic letters》.2012 |
| Houttuynoids A-E, anti-herpes simplex virus active flavonoids with novel skeletons from Houttuynia cordata;Chen SD et al;《organic letters》;20120313;第7卷(第14期);第1772-1775页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102872140A (en) | 2013-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102872115B (en) | Application of Houttuynoid A in preparing medicament for treating acute renal failure | |
| CN102872140B (en) | Application of Houttuynoid C in drug for treating acute renal failure | |
| CN102861095B (en) | Application of Houttuynoid E in medicine for treating acute renal failure | |
| CN103599102B (en) | Application of Nitrosporeusines A in drugs for treating acute renal failure | |
| CN102872094A (en) | Application of Houttuynoid B in medicine for treating acute renal failure | |
| CN103251637A (en) | Application of Polyflavanostilbene A in preparing medicine for treating acute renal failure | |
| CN102861008A (en) | Application of Aphanamixoid A in medicine for treating acute renal failure | |
| CN103356605B (en) | Application of Chukrasone B in preparing medicines for treating acute renal failure | |
| CN107308121A (en) | The therapeutic agent of liver regeneration | |
| CN103127151A (en) | Application of Gypensapogenin A in medicines treating acute renal failure | |
| CN102872097A (en) | Application of Houttuynoid D in medicine for treating acute renal failure | |
| CN103356646A (en) | Application of Chukrasone A in preparation of medicines for treating acute renal failure | |
| CN103599105B (en) | Application of Caesanines D in drugs used for treating acute renal failure | |
| CN103356543A (en) | Application of Sarcaboside A in preparation of drug for treating acute renal failure | |
| CN103655538B (en) | The application of Hippolachnin A in treatment acute renal failure medicine | |
| CN103356527A (en) | Application of Sarcaboside B in medicine used for treating acute renal failure | |
| CN103462996A (en) | Application of Neonectrolide A in preparing medicament for treating acute renal failure | |
| CN103446119B (en) | Application of Fluevirosines A in preparation of acute renal failure treating drug | |
| CN103127069A (en) | Application of Eryngiolide A in medicines treating acute renal failure | |
| CN103520172B (en) | The application of Kadcoccitones A in preparation treatment acute renal failure medicine | |
| CN103463009A (en) | Application of racemosins A in preparation of medicine treating acute renal failure | |
| CN102895242A (en) | Application of Gypensapogenin B in drugs for treating acute renal failure | |
| CN103340877A (en) | Application of Aspeverin in preparation of medicine for treating acute renal failure | |
| CN105287481A (en) | Application of Concrescenin A in preparation of medicine for treating acute renal failure | |
| CN105456238A (en) | Application of Norsampsone A in preparation of drug for treating acute renal failure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: FENG MINGSHAN Free format text: FORMER OWNER: WU JUNHUA Effective date: 20141201 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 210009 NANJING, JIANGSU PROVINCE TO: 226400 NANTONG, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20141201 Address after: 226400 No. three, No. 41, Haihe Beach village, Yuan Zhen, Jiangsu County, Rudong Patentee after: Feng Mingshan Address before: 210009 No. 22, Hankou Road, Gulou District, Jiangsu, Nanjing Patentee before: Wu Junhua |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130828 Termination date: 20151027 |
|
| EXPY | Termination of patent right or utility model |